Our analysis models the clinical and economic value of fidaxomicin for the treatment of Clostridium difficile infection compared with metronidazole and vancomycin.
John P. Caloyeras, MPhil
Advertisement
Articles by John P. Caloyeras, MPhil
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on Pharmacy Times
1
Suzetrigine Nears 1 Million Prescriptions as Reimbursed Access Expands for Nonopioid Acute Pain Treatment
2
Cervical Cancer Screening and HPV Self-Collection: What Pharmacists Want Patients to Know
3
Pharmacy’s Role in Implementing Pafolacianine for Fluorescence-Guided Lung Cancer Surgery
4
From Treatment to Prevention: How Pharmacists Are Refining CRS Management for Bispecific Antibody Therapy
5